Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ.
2012.
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
[Online].
London School of Hygiene & Tropical Medicine, London, United Kingdom.
Available from:
https://doi.org/10.17037/DATA.24.
Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ.
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
[Internet].
London School of Hygiene & Tropical Medicine;
2012.
Available from:
https://doi.org/10.17037/DATA.24.
Sheehy, SH, Duncan, CJA, Elias, SC, Biswas, S, Collins, KA, O'hara, G, Halstead, FD, Ewer, KJ, Mahungu, T, Spencer, AJ, Miura, K, Poulton, ID, Dicks, MDJ, Edwards, NJ, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, CA, Lawrie, AM, Gilbert, SC, Doherty, T, Nicosia, A, Hill, AVS and Draper, SJ
(2012).
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
[Data Collection].
London School of Hygiene & Tropical Medicine, London, United Kingdom.
https://doi.org/10.17037/DATA.24.
Description
Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection in a pre-specified primary endpoint of a Phase IIa/b clinical trial designed to assess vaccine efficacy. Cell-mediated responses, acting in conjunction with functional antibodies, may be necessary for immunity against blood-stage P. falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question.
